• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Vaccines Market Access in India – New Vaccine Uptake Drives Growth Product Image

Vaccines Market Access in India – New Vaccine Uptake Drives Growth

  • Published: April 2012
  • Region: India
  • 77 Pages
  • Datamonitor

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Sanofi Pasteur
  • MORE

This report analyzes the vaccine market in India, and provides recommendations for both local manufacturers operating in the space and Western players looking to enter into this lucrative market.

The government-sponsored Universal Immunization Program procures vaccines at very low prices, predominantly from local manufacturers. There also exists a large private market for vaccines which is dominated by multinational companies. The private market for newer and better vaccines is growing due to the increasing affordability of the middle class population.

Scope

- Review the current regulatory processes, pricing mechanisms, and vaccination schedule in India.
- Identify major multinational and domestic players, view their product portfolios and pipelines, and understand their expansion strategies.
- Examine the major drivers and resistors of the current Indian vaccine market and understand the key opportunities and threats facing developers.

Highlights

- India is the world's largest producer of vaccines: 60% of the world’s vaccines are manufactured in the country and it accounts for 60–80% of annual UN vaccine purchases. The Indian government READ MORE >

OVERVIEW
- Catalyst
- Summary

EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the Indian vaccines market
- Related reports

MARKET OVERVIEW
- Historic development
- - Vaccine policy in India post-independence

- Current market situation
- Regulatory process for vaccines
- Vaccination recommendations
- - Introduction of new vaccines in the NIS and IAP recommendations

- Vaccine pricing
- - Pricing of vaccines included in the UIP
- - Pricing of optional vaccines that are not included in the UIP

- Vaccine reimbursement
- Vaccine distribution and access
- Vaccination coverage

KEY COMPANIES ACTIVE IN THE INDIAN VACCINES MARKET
- Key findings
- Industry overview
- - General overview

- Multinational vaccine companies in India
- - GlaxoSmithKline
- - Merck Sharp & Dohme
- - Novartis
- - Sanofi Pasteur

- Domestic vaccine companies
- - Bharat Biotech
- - Biological E
- - Bio-Med
- - Indian Immunologicals
- - Panacea Biotec
- - Serum Institute of India

STRATEGIC RECOMMENDATIONS FOR MARKET ACCESS
- Key findings
- Key future target indications
- SWOT analysis of India as a target market for vaccines
- Drivers and resistors
- - Drivers
- - Resistors

- Best strategy for market penetration
- - Partnership with local companies will help multinationals increase their market coverage
- - Setting up of vaccine manufacturing facility in India will be advantageous
- - Inclusion of new vaccines into the immunization schedule is critical for domestic and Western vaccine manufacturers

BIBLIOGRAPHY
- Journals
- Websites
- Datamonitor reports

APPENDIX
- Contributing experts
- Conferences attended
- Report methodology

TABLES

Table: India: estimated number of vaccine doses distributed for key indications, 2010
Table: Price of optional vaccines in the Indian private sector, 2011
Table: Vaccination recommendations and reimbursement status in India, 2011
Table: Biotech sales of key vaccine players in India ($m), 2011
Table: Vaccine portfolio of multinational companies in India, 2011
Table: Vaccine portfolio of domestic companies, 2011
Table: GlaxoSmithKline: human vaccine portfolio and pipeline overview in India, 2011
Table: Merck Sharp & Dohme: human vaccine portfolio and pipeline overview in India, 2011
Table: Merck Sharp & Dohme: key vaccine deals and alliances in India, 2011
Table: Novartis: human vaccine portfolio and pipeline overview in India, 2011
Table: Novartis: key vaccine deals and alliances in India, 2011
Table: Sanofi: human vaccine portfolio and pipeline overview in India, 2011
Table: Sanofi: key vaccine deals and alliances in India, 2011
Table: Bharat Biotech: human vaccine portfolio and pipeline overview, 2011
Table: Bharat Biotech: key vaccine deals and alliances, 2011
Table: Biological E: human vaccine portfolio and pipeline overview, 2011
Table: Biological E: key vaccine deals and alliances, 2011
Table: Bio-Med: human vaccine portfolio and pipeline overview, 2011
Table: Indian Immunologicals: human vaccine portfolio and pipeline overview, 2011
Table: Panacea Biotec (including Chiron Panacea): human vaccine portfolio and pipeline overview, 2011
Table: Panacea Biotec: key vaccine deals and alliances, 2011
Table: Serum Institute of India: human vaccine portfolio and pipeline overview, 2011
Table: Serum Institute of India: key vaccine deals and alliances, 2011
Table: Shantha Biotech: human vaccine portfolio and pipeline overview, 2011
Table: Shantha Biotech: key vaccine deals and alliances, 2011
Table: SWOT analysis of the Indian vaccines market, 2011
Table: India versus selected countries: National immunization Schedule comparison, 2011
Table: Key partnerships of multinational corporation with local vaccine players in India, 2011

FIGURES

Figure: Timeline of vaccine development in India, 1960-2005
Figure: Vaccines regulatory approval pathway in India, 2011
Figure: National Immunization Schedule of India, 2010
Figure: Indian Academy of Pediatrics immunization schedule, 2011
Figure: Distribution of UIP vaccines in India, 2011
Figure: Distribution of vaccines in the private sector, 2011
Figure: Percentage of children aged 12-23 months in India who have received all vaccinations, by state, 2009
Figure: Percentage of children aged 12-23 months in India who have received hepatitis B vaccination, by state, 2009
Figure: Key future target indications in India, 2011
Figure: Drivers and resistors that will impact the vaccines market in India, 2011
Figure: India: population indicators from 1950 to 2050
Figure: Proportion of government and private health expenditure versus personal disposable income, in India and other major markets, 2009

- GlaxoSmithKline
- Merck Sharp & Dohme
- Novartis
- Sanofi Pasteur

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos